Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oprozomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**oprozomib + dexamethasone** is an investigational oral combination therapy primarily evaluated for treatment of **relapsed and refractory multiple myeloma (RRMM)**. Oprozomib is an **irreversible oral proteasome inhibitor** structurally related to carfilzomib, acting through inhibition of the chymotrypsin-like activity of the proteasome, leading to apoptosis and anti-angiogenic effects in myeloma cells[1][3]. Dexamethasone is a synthetic glucocorticoid widely used for its **immunosuppressive and anti-inflammatory properties** and is included to enhance cytotoxicity against myeloma cells. The combination has been studied for its tolerability and efficacy in phase 1b/2 trials in RRMM patients, showing promising anti-myeloma activity, but also exhibiting dose-limiting toxicities such as thrombocytopenia and transaminitis. No unique brand name is assigned to this combination as it is used in clinical trials rather than commercialized.
- Other names
- OPZ + DexOPZ-DEXoprozomib + dexamethasone
02
Targets
PSMB5 (Proteasome subunit beta Type-5)PSMB8 (Immunoproteasome)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on oprozomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oprozomib + dexamethasone.